$1.16
6.10% today
NYSE, Apr 04, 07:15 pm CET
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Adc Therapeutics SA Target price 2025 - Analyst rating & recommendation

Adc Therapeutics SA Classifications & Recommendation:

Buy
100%

Adc Therapeutics SA Price Target

Target Price $8.20
Price $1.23
Potential
Number of Estimates 5
5 Analysts have issued a price target Adc Therapeutics SA 2026 . The average Adc Therapeutics SA target price is $8.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 6 Analysts recommend Adc Therapeutics SA to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Adc Therapeutics SA stock has an average upside potential 2026 of . Most analysts recommend the Adc Therapeutics SA stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 70.84 73.42
1.84% 3.65%
Net Margin -226.08% -218.34%
45.89% 3.42%

6 Analysts have issued a sales forecast Adc Therapeutics SA 2025 . The average Adc Therapeutics SA sales estimate is

$73.4m
Unlock
. This is
3.65% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$76.1m 7.37%
Unlock
, the lowest is
$69.6m 1.75%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $70.8m 1.84%
2025
$73.4m 3.65%
Unlock
2026
$88.0m 19.79%
Unlock
2027
$149m 69.65%
Unlock
2028
$268m 79.48%
Unlock
2029
$382m 42.72%
Unlock

6 Adc Therapeutics SA Analysts have issued a net profit forecast 2025. The average Adc Therapeutics SA net profit estimate is

$-160m
Unlock
. This is
2.31% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-125m 24.10%
Unlock
, the lowest is
$-222m 35.55%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-160m 44.90%
2025
$-160m 0.10%
Unlock
2026
$-132m 17.86%
Unlock
2027
$-94.5m 28.23%
Unlock
2028
$-35.6m 62.34%
Unlock
2029
$23.2m 165.27%
Unlock

Net Margin

2024 -226.08% 45.89%
2025
-218.34% 3.42%
Unlock
2026
-149.71% 31.43%
Unlock
2027
-63.34% 57.69%
Unlock
2028
-13.29% 79.02%
Unlock
2029
6.08% 145.75%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.62 -1.62
44.90% 0.00%
P/E negative
EV/Sales negative

6 Analysts have issued a Adc Therapeutics SA forecast for earnings per share. The average Adc Therapeutics SA EPS is

$-1.62
Unlock
. This is
2.41% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.26 24.10%
Unlock
, the lowest is
$-2.25 35.54%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.62 44.90%
2025
$-1.62 0.00%
Unlock
2026
$-1.33 17.90%
Unlock
2027
$-0.96 27.82%
Unlock
2028
$-0.36 62.50%
Unlock
2029
$0.24 166.67%
Unlock

P/E ratio

Current -0.74 51.63%
2025
-0.76 2.70%
Unlock
2026
-0.92 21.05%
Unlock
2027
-1.29 40.22%
Unlock
2028
-3.42 165.12%
Unlock
2029
5.23 252.92%
Unlock

Based on analysts' sales estimates for 2025, the Adc Therapeutics SA stock is valued at an EV/Sales of

-0.08
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.08 102.57%
2025
-0.08 2.13%
Unlock
2026
-0.07 16.52%
Unlock
2027
-0.04 41.06%
Unlock
2028
-0.02 44.28%
Unlock
2029
-0.02 29.91%
Unlock

P/S ratio

Current 1.72 67.71%
2025
1.66 3.52%
Unlock
2026
1.39 16.52%
Unlock
2027
0.82 41.06%
Unlock
2028
0.46 44.28%
Unlock
2029
0.32 29.95%
Unlock

Current Adc Therapeutics SA Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
Locked
Locked Mar 31 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 31 2025
Cantor Fitzgerald
Locked
Locked
Locked Mar 07 2025
Stephens & Co.
Locked
Locked
Locked Feb 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 06 2025
Guggenheim
Locked
Locked
Locked Dec 12 2024
HC Wainwright & Co.
Locked
Locked
Locked Dec 11 2024
Analyst Rating Date
Locked
Guggenheim:
Locked
Locked
Mar 31 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 31 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 07 2025
Locked
Stephens & Co.:
Locked
Locked
Feb 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 06 2025
Locked
Guggenheim:
Locked
Locked
Dec 12 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today